Skip to main content
Top
Published in: BMC Gastroenterology 1/2023

Open Access 01-12-2023 | Chronic Inflammatory Bowel Disease | Research

Macrophage polarization toward M1 phenotype in T cell transfer colitis model

Authors: Shin Ebihara, Toshiki Urashima, Wataru Amano, Hideto Yamamura, Noriko Konishi

Published in: BMC Gastroenterology | Issue 1/2023

Login to get access

Abstract

Background

T cell transfer colitis model is often used to study the CD4+ T cell functions in the intestine. However, the specific roles of macrophages in colitis remain unclear. In this study, we aimed to evaluate the phenotype and functions of macrophages in the colonic lamina propria (LP) in a colitis model.

Methods

Colitis was induced in scid mice via the adaptive transfer of CD4+CD45RBhi T cells. Then, flow cytometry was used to determine the number of macrophages in the colonic LP and expression of cytokines in macrophages at the onset of colitis. Moreover, M1/M2 macrophage markers were detected in the colonic LP during colitis development using high-dimensional single-cell data and gating-based analyses. Expression levels of M1 markers in macrophages isolated from the colonic LP were measured using quantitative reverse transcription-polymerase chain reaction. Additionally, macrophages were co-cultured with T cells isolated from the colon to assess colitogenic T cell activation.

Results

Infiltration of macrophages into the colon increased with the development of colitis in the T cell transfer colitis model. M1/M2 macrophage markers were observed in this model, as observed in the colon of patients with inflammatory bowel disease (IBD). Moreover, number of M1 macrophages increased, whereas that of M2 macrophages decreased in the colonic LP during colitis development. M1 macrophages were identified as the main source of inflammatory cytokine production, and colitogenic T cells were activated via interactions with these macrophages.

Conclusions

Our findings revealed that macrophages polarized toward the M1 phenotype in LP during colitis development in the T cell transfer colitis model. Therefore, the colitis model is suitable for the evaluation of the efficacy of macrophage-targeted drugs in human IBD treatment. Furthermore, this model can be used to elucidate the in vivo functions of macrophages in the colon of patients with IBD.
Appendix
Available only for authorised users
Literature
1.
go back to reference Gomollón F, Dignass A, Annese V, Tilg H, Van Assche G, Lindsay JO, et al. 3rd European evidence-based Consensus on the diagnosis and management of Crohn’s Disease 2016: part 1: diagnosis and Medical Management. J Crohns Colitis. 2017;11:3–25.CrossRefPubMed Gomollón F, Dignass A, Annese V, Tilg H, Van Assche G, Lindsay JO, et al. 3rd European evidence-based Consensus on the diagnosis and management of Crohn’s Disease 2016: part 1: diagnosis and Medical Management. J Crohns Colitis. 2017;11:3–25.CrossRefPubMed
2.
go back to reference Magro F, Gionchetti P, Eliakim R, Ardizzone S, Armuzzi A, Barreiro-de Acosta M, et al. Third European evidence-based Consensus on diagnosis and management of Ulcerative Colitis. Part 1: definitions, Diagnosis, extra-intestinal manifestations, pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch disorders. J Crohns Colitis. 2017;11:649–70.CrossRefPubMed Magro F, Gionchetti P, Eliakim R, Ardizzone S, Armuzzi A, Barreiro-de Acosta M, et al. Third European evidence-based Consensus on diagnosis and management of Ulcerative Colitis. Part 1: definitions, Diagnosis, extra-intestinal manifestations, pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch disorders. J Crohns Colitis. 2017;11:649–70.CrossRefPubMed
3.
go back to reference Colombel JF, D’haens G, Lee WJ, Petersson J, Panaccione R. Outcomes and strategies to support a treat-to-target Approach in Inflammatory Bowel Disease: a systematic review. J Crohns Colitis. 2020;14:254–66.CrossRefPubMed Colombel JF, D’haens G, Lee WJ, Petersson J, Panaccione R. Outcomes and strategies to support a treat-to-target Approach in Inflammatory Bowel Disease: a systematic review. J Crohns Colitis. 2020;14:254–66.CrossRefPubMed
4.
go back to reference Singh S, George J, Boland BS, Vande Casteele N, Sandborn WJ. Primary non-response to Tumor Necrosis Factor Antagonists Is Associated with Inferior response to second-line Biologics in patients with inflammatory Bowel Diseases: a systematic review and Meta-analysis. J Crohns Colitis. 2018:12635–43. Singh S, George J, Boland BS, Vande Casteele N, Sandborn WJ. Primary non-response to Tumor Necrosis Factor Antagonists Is Associated with Inferior response to second-line Biologics in patients with inflammatory Bowel Diseases: a systematic review and Meta-analysis. J Crohns Colitis. 2018:12635–43.
5.
go back to reference Fumery M, Peyrin-Biroulet L, Nancey S, Altwegg R, Gilletta C, Veyrard P et al. Effectiveness And Safety Of Ustekinumab Intensification At 90 Mg Every Four Weeks In Crohn’s Disease: A Multicenter Study. J Crohns Colitis. 2020:jjaa177. Fumery M, Peyrin-Biroulet L, Nancey S, Altwegg R, Gilletta C, Veyrard P et al. Effectiveness And Safety Of Ustekinumab Intensification At 90 Mg Every Four Weeks In Crohn’s Disease: A Multicenter Study. J Crohns Colitis. 2020:jjaa177.
6.
7.
go back to reference Bilsborough J, Fiorino MF, Henkle BW. Select animal models of Colitis and their value in predicting clinical efficacy of biological therapies in ulcerative Colitis. Expert Opin Drug Discov. 2021;16:567–77.CrossRefPubMed Bilsborough J, Fiorino MF, Henkle BW. Select animal models of Colitis and their value in predicting clinical efficacy of biological therapies in ulcerative Colitis. Expert Opin Drug Discov. 2021;16:567–77.CrossRefPubMed
8.
go back to reference Katsandegwaza B, Horsnell W, Smith KI, nflammatory Bowel Disease. A review of pre-clinical murine models of Human Disease. Int J Mol Sci. 2022;23:9344.CrossRefPubMedPubMedCentral Katsandegwaza B, Horsnell W, Smith KI, nflammatory Bowel Disease. A review of pre-clinical murine models of Human Disease. Int J Mol Sci. 2022;23:9344.CrossRefPubMedPubMedCentral
9.
go back to reference te Velde AA, de Kort F, Sterrenburg E, Pronk I, ten Kate FJ, Hommes DW, et al. Comparative analysis of colonic gene expression of three experimental Colitis models mimicking inflammatory bowel Disease. Inflamm Bowel Dis. 2007;13:325–30.CrossRef te Velde AA, de Kort F, Sterrenburg E, Pronk I, ten Kate FJ, Hommes DW, et al. Comparative analysis of colonic gene expression of three experimental Colitis models mimicking inflammatory bowel Disease. Inflamm Bowel Dis. 2007;13:325–30.CrossRef
10.
go back to reference Koboziev I, Karlsson F, Zhang S, Grisham MB. Pharmacological intervention studies using mouse models of the inflammatory bowel Diseases: translating preclinical data into new drug therapies. Inflamm Bowel Dis. 2011;17:1229–45.CrossRefPubMed Koboziev I, Karlsson F, Zhang S, Grisham MB. Pharmacological intervention studies using mouse models of the inflammatory bowel Diseases: translating preclinical data into new drug therapies. Inflamm Bowel Dis. 2011;17:1229–45.CrossRefPubMed
11.
go back to reference Ostanin DV, Bao J, Koboziev I, Gray L, Robinson-Jackson SA, Kosloski-Davidson M, et al. T cell transfer model of chronic Colitis: concepts, considerations, and tricks of the trade. Am J Physiol Gastrointest Liver Physiol. 2009;296:G135–46.CrossRefPubMed Ostanin DV, Bao J, Koboziev I, Gray L, Robinson-Jackson SA, Kosloski-Davidson M, et al. T cell transfer model of chronic Colitis: concepts, considerations, and tricks of the trade. Am J Physiol Gastrointest Liver Physiol. 2009;296:G135–46.CrossRefPubMed
12.
go back to reference Harbour SN, Maynard CL, Zindl CL, Schoeb TR, Weaver CT. Th17 cells give rise to Th1 cells that are required for the pathogenesis of Colitis. Proc Natl Acad Sci U S A. 2015;112:7061–6.CrossRefPubMedPubMedCentral Harbour SN, Maynard CL, Zindl CL, Schoeb TR, Weaver CT. Th17 cells give rise to Th1 cells that are required for the pathogenesis of Colitis. Proc Natl Acad Sci U S A. 2015;112:7061–6.CrossRefPubMedPubMedCentral
13.
go back to reference Britton GJ, Contijoch EJ, Mogno I, Vennaro OH, Llewellyn SR, Ng R, et al. Microbiotas from humans with inflammatory bowel Disease alter the balance of Gut Th17 and RORγt+ Regulatory T cells and exacerbate Colitis in mice. Immunity. 2019;50:212–24.CrossRefPubMedPubMedCentral Britton GJ, Contijoch EJ, Mogno I, Vennaro OH, Llewellyn SR, Ng R, et al. Microbiotas from humans with inflammatory bowel Disease alter the balance of Gut Th17 and RORγt+ Regulatory T cells and exacerbate Colitis in mice. Immunity. 2019;50:212–24.CrossRefPubMedPubMedCentral
14.
go back to reference Shouval DS, Biswas A, Goettel JA, McCann K, Conaway E, Redhu NS, et al. Interleukin-10 receptor signaling in innate immune cells regulates mucosal immune tolerance and anti-inflammatory macrophage function. Immunity. 2014;40:706–19.CrossRefPubMedPubMedCentral Shouval DS, Biswas A, Goettel JA, McCann K, Conaway E, Redhu NS, et al. Interleukin-10 receptor signaling in innate immune cells regulates mucosal immune tolerance and anti-inflammatory macrophage function. Immunity. 2014;40:706–19.CrossRefPubMedPubMedCentral
15.
go back to reference Na YR, Stakenborg M, Seok SH, Matteoli G. Macrophages in intestinal inflammation and resolution: a potential therapeutic target in IBD. Nat Rev Gastroenterol Hepatol. 2019;16:531–43.CrossRefPubMed Na YR, Stakenborg M, Seok SH, Matteoli G. Macrophages in intestinal inflammation and resolution: a potential therapeutic target in IBD. Nat Rev Gastroenterol Hepatol. 2019;16:531–43.CrossRefPubMed
16.
go back to reference Lissner D, Schumann M, Batra A, Kredel LI, Kühl AA, Erben U, et al. Monocyte and M1 macrophage-induced barrier defect contributes to chronic intestinal inflammation in IBD. Inflamm Bowel Dis. 2015;21:1297–305.PubMed Lissner D, Schumann M, Batra A, Kredel LI, Kühl AA, Erben U, et al. Monocyte and M1 macrophage-induced barrier defect contributes to chronic intestinal inflammation in IBD. Inflamm Bowel Dis. 2015;21:1297–305.PubMed
17.
go back to reference Bernardo D, Marin AC, Fernández-Tomé S, Montalban-Arques A, Carrasco A, Tristán E, et al. Human intestinal pro-inflammatory CD11chighCCR2+CX3CR1+ macrophages, but not their tolerogenic CD11c CCR2 CX3CR1 counterparts, are expanded in inflammatory bowel Disease. Mucosal Immunol. 2018;11:1114–26.CrossRefPubMed Bernardo D, Marin AC, Fernández-Tomé S, Montalban-Arques A, Carrasco A, Tristán E, et al. Human intestinal pro-inflammatory CD11chighCCR2+CX3CR1+ macrophages, but not their tolerogenic CD11c CCR2 CX3CR1 counterparts, are expanded in inflammatory bowel Disease. Mucosal Immunol. 2018;11:1114–26.CrossRefPubMed
18.
go back to reference Read S, Powrie F. Induction of inflammatory bowel Disease in immunodeficient mice by depletion of regulatory T cells. Curr Protoc Immunol. 2001;Chap. 15:Unit 15.13. Read S, Powrie F. Induction of inflammatory bowel Disease in immunodeficient mice by depletion of regulatory T cells. Curr Protoc Immunol. 2001;Chap. 15:Unit 15.13.
19.
go back to reference Becker C, Fantini MC, Neurath MF. High resolution colonoscopy in live mice. Nat Protoc. 2006;1:2900–4.CrossRefPubMed Becker C, Fantini MC, Neurath MF. High resolution colonoscopy in live mice. Nat Protoc. 2006;1:2900–4.CrossRefPubMed
20.
go back to reference Koelink PJ, Wildenberg ME, Stitt LW, Feagan BG, Koldijk M, van ‘t Wout AB, et al. Development of Reliable, valid and responsive Scoring systems for Endoscopy and Histology in Animal models for Inflammatory Bowel Disease. J Crohns Colitis. 2018;12:794–803.CrossRefPubMedPubMedCentral Koelink PJ, Wildenberg ME, Stitt LW, Feagan BG, Koldijk M, van ‘t Wout AB, et al. Development of Reliable, valid and responsive Scoring systems for Endoscopy and Histology in Animal models for Inflammatory Bowel Disease. J Crohns Colitis. 2018;12:794–803.CrossRefPubMedPubMedCentral
21.
go back to reference Erben U, Loddenkemper C, Doerfel K, Spieckermann S, Haller D, Heimesaat MM, et al. A guide to histomorphological evaluation of intestinal inflammation in mouse models. Int J Clin Exp Pathol. 2014;7:4557–76.PubMedPubMedCentral Erben U, Loddenkemper C, Doerfel K, Spieckermann S, Haller D, Heimesaat MM, et al. A guide to histomorphological evaluation of intestinal inflammation in mouse models. Int J Clin Exp Pathol. 2014;7:4557–76.PubMedPubMedCentral
22.
go back to reference Corbin AL, Gomez-Vazquez M, Berthold DL, Attar M, Arnold IC, Powrie FM, et al. IRF5 guides monocytes toward an inflammatory CD11c+ macrophage phenotype and promotes intestinal inflammation. Sci Immunol. 2020;5:eaax6085.CrossRefPubMedPubMedCentral Corbin AL, Gomez-Vazquez M, Berthold DL, Attar M, Arnold IC, Powrie FM, et al. IRF5 guides monocytes toward an inflammatory CD11c+ macrophage phenotype and promotes intestinal inflammation. Sci Immunol. 2020;5:eaax6085.CrossRefPubMedPubMedCentral
23.
go back to reference Han C, Sheng Y, Wang J, Zhou X, Li W, Zhang C, et al. NOX4 promotes mucosal barrier injury in inflammatory bowel Disease by mediating macrophages M1 polarization through ROS. Int Immunopharmacol. 2022;104:108361.CrossRefPubMed Han C, Sheng Y, Wang J, Zhou X, Li W, Zhang C, et al. NOX4 promotes mucosal barrier injury in inflammatory bowel Disease by mediating macrophages M1 polarization through ROS. Int Immunopharmacol. 2022;104:108361.CrossRefPubMed
24.
go back to reference Macias-Ceja DC, Cosín-Roger J, Ortiz-Masiá D, Salvador P, Hernández C, Esplugues JV, et al. Stimulation of autophagy prevents intestinal mucosal inflammation and ameliorates murine Colitis. Br J Pharmacol. 2017;174:2501–11.CrossRefPubMedPubMedCentral Macias-Ceja DC, Cosín-Roger J, Ortiz-Masiá D, Salvador P, Hernández C, Esplugues JV, et al. Stimulation of autophagy prevents intestinal mucosal inflammation and ameliorates murine Colitis. Br J Pharmacol. 2017;174:2501–11.CrossRefPubMedPubMedCentral
25.
go back to reference Cosín-Roger J, Ortiz-Masiá D, Calatayud S, Hernández C, Alvarez A, Hinojosa J, et al. M2 macrophages activate WNT signaling pathway in epithelial cells: relevance in ulcerative Colitis. PLoS ONE. 2013;8:e78128.CrossRefPubMedPubMedCentral Cosín-Roger J, Ortiz-Masiá D, Calatayud S, Hernández C, Alvarez A, Hinojosa J, et al. M2 macrophages activate WNT signaling pathway in epithelial cells: relevance in ulcerative Colitis. PLoS ONE. 2013;8:e78128.CrossRefPubMedPubMedCentral
26.
go back to reference Wright PB, McDonald E, Bravo-Blas A, Baer HM, Heawood A, Bain CC, et al. The mannose receptor (CD206) identifies a population of colonic macrophages in health and inflammatory bowel Disease. Sci Rep. 2021;11:19616.CrossRefPubMedPubMedCentral Wright PB, McDonald E, Bravo-Blas A, Baer HM, Heawood A, Bain CC, et al. The mannose receptor (CD206) identifies a population of colonic macrophages in health and inflammatory bowel Disease. Sci Rep. 2021;11:19616.CrossRefPubMedPubMedCentral
27.
go back to reference Ma S, Zhang J, Liu H, Li S, Wang Q. The role of tissue-Resident macrophages in the Development and Treatment of Inflammatory Bowel Disease. Front Cell Dev Biol. 2022;10:896591.CrossRefPubMedPubMedCentral Ma S, Zhang J, Liu H, Li S, Wang Q. The role of tissue-Resident macrophages in the Development and Treatment of Inflammatory Bowel Disease. Front Cell Dev Biol. 2022;10:896591.CrossRefPubMedPubMedCentral
28.
go back to reference Mowat AM. To respond or not to respond - a personal perspective of intestinal tolerance. Nat Rev Immunol. 2018;18:405–15.CrossRefPubMed Mowat AM. To respond or not to respond - a personal perspective of intestinal tolerance. Nat Rev Immunol. 2018;18:405–15.CrossRefPubMed
29.
go back to reference Murray PJ, Allen JE, Biswas SK, Fisher EA, Gilroy DW, Goerdt S, et al. Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity. 2014;41:14–20.CrossRefPubMedPubMedCentral Murray PJ, Allen JE, Biswas SK, Fisher EA, Gilroy DW, Goerdt S, et al. Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity. 2014;41:14–20.CrossRefPubMedPubMedCentral
30.
go back to reference Jablonski KA, Amici SA, Webb LM, Ruiz-Rosado Jde D, Popovich PG, Partida-Sanchez S, et al. Novel markers to delineate murine M1 and M2 macrophages. PLoS ONE. 2015;10:e0145342.CrossRefPubMedPubMedCentral Jablonski KA, Amici SA, Webb LM, Ruiz-Rosado Jde D, Popovich PG, Partida-Sanchez S, et al. Novel markers to delineate murine M1 and M2 macrophages. PLoS ONE. 2015;10:e0145342.CrossRefPubMedPubMedCentral
31.
go back to reference Orecchioni M, Ghosheh Y, Pramod AB, Ley K. Macrophage polarization: different gene signatures in M1(LPS+) vs. classically and M2(LPS-) vs. alternatively activated macrophages. Front Immunol. 2019;10:1084.CrossRefPubMedPubMedCentral Orecchioni M, Ghosheh Y, Pramod AB, Ley K. Macrophage polarization: different gene signatures in M1(LPS+) vs. classically and M2(LPS-) vs. alternatively activated macrophages. Front Immunol. 2019;10:1084.CrossRefPubMedPubMedCentral
32.
go back to reference Du Y, Rong L, Cong Y, Shen L, Zhang N, Wang B. Macrophage polarization: an effective approach to targeted therapy of inflammatory bowel Disease. Expert Opin Ther Targets. 2021;25:191–209.CrossRefPubMed Du Y, Rong L, Cong Y, Shen L, Zhang N, Wang B. Macrophage polarization: an effective approach to targeted therapy of inflammatory bowel Disease. Expert Opin Ther Targets. 2021;25:191–209.CrossRefPubMed
33.
go back to reference Seyedizade SS, Afshari K, Bayat S, Rahmani F, Momtaz S, Rezaei N, et al. Current status of M1 and M2 macrophages pathway as drug targets for inflammatory bowel Disease. Arch Immunol Ther Exp (Warsz). 2020;68:10.CrossRefPubMed Seyedizade SS, Afshari K, Bayat S, Rahmani F, Momtaz S, Rezaei N, et al. Current status of M1 and M2 macrophages pathway as drug targets for inflammatory bowel Disease. Arch Immunol Ther Exp (Warsz). 2020;68:10.CrossRefPubMed
34.
go back to reference Rogler G. Resolution of inflammation in inflammatory bowel Disease. Lancet Gastroenterol Hepatol. 2017;2:521–30.CrossRefPubMed Rogler G. Resolution of inflammation in inflammatory bowel Disease. Lancet Gastroenterol Hepatol. 2017;2:521–30.CrossRefPubMed
35.
go back to reference Chiaranunt P, Tometich JT, Ji J, Hand TW. T cell proliferation and Colitis are initiated by defined intestinal microbes. J Immunol. 2018;201:243–50.CrossRefPubMed Chiaranunt P, Tometich JT, Ji J, Hand TW. T cell proliferation and Colitis are initiated by defined intestinal microbes. J Immunol. 2018;201:243–50.CrossRefPubMed
36.
go back to reference Spindler MP, Mogno I, Suri P, Britton GJ, Faith JJ. Species-specific CD4+ T cells enable prediction of mucosal immune phenotypes from microbiota composition. Proc Natl Acad Sci U S A. 2023;120:e2215914120.CrossRefPubMedPubMedCentral Spindler MP, Mogno I, Suri P, Britton GJ, Faith JJ. Species-specific CD4+ T cells enable prediction of mucosal immune phenotypes from microbiota composition. Proc Natl Acad Sci U S A. 2023;120:e2215914120.CrossRefPubMedPubMedCentral
37.
go back to reference Mestas J, Hughes CC. Of mice and not men: differences between mouse and human immunology. J Immunol. 2004;172:2731–8.CrossRefPubMed Mestas J, Hughes CC. Of mice and not men: differences between mouse and human immunology. J Immunol. 2004;172:2731–8.CrossRefPubMed
Metadata
Title
Macrophage polarization toward M1 phenotype in T cell transfer colitis model
Authors
Shin Ebihara
Toshiki Urashima
Wataru Amano
Hideto Yamamura
Noriko Konishi
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Gastroenterology / Issue 1/2023
Electronic ISSN: 1471-230X
DOI
https://doi.org/10.1186/s12876-023-03054-1

Other articles of this Issue 1/2023

BMC Gastroenterology 1/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.